Covaxin has been found to be effective against coronavirus strains found in India and the UK, said Bharat Biotech on Sunday.
Citing a study published in the peer-reviewed medical journal Clinical Infectious Diseases, the Indian biotechnology company headquartered in Hyderabad, said vaccination with Covaxin produced neutralizing titers against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK.
The study was conducted in collaboration with the National Institute of Virology and Indian Council of Medical Research, reported PTI.
“Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap,” Bharat Biotech co-founder and Joint Managing Director Suchitra Ella said in a tweet. She also tagged PMO India, Finance Minister Nirmala Sitharaman, and Health Minister Harsh Vardhan, among others, in the tweet.
Meanwhile, the Health Ministry has said nearly 51 lakh COVID-19 vaccine doses are in the pipeline and states will receive doses in the next 3 days.
It further said that more than 1.84 crore vaccine doses are still available with states and Union Territories.
Meanwhile, Bharat Biotech International Ltd will soon start manufacturing vaccines in Pune, through subsidiary Biovet Pvt Ltd.
Maharashtra Deputy Chief Minister Ajit Pawar announced on Friday.
“It will take around three months for the company to start production of vaccines from this facility,” Pawar told media persons.